Elicio Therapeutics grants 21,750 options at $2.70
Elicio Therapeutics, Inc. (ELTX) reported that director Karen J. Wilson received a grant of 21,750 stock options on August 31, 2026 as an annual non-employee director equity award.
Rhea-AI Filing Summary
Elicio Therapeutics, Inc. (ELTX) reported that director Karen J. Wilson received a grant of 21,750 stock options on August 31, 2026 as an annual non-employee director equity award. The options have an exercise price of $2.70 per share, expire on August 31, 2036, and cover 21,750 shares of common stock.
The award will vest and become exercisable in full on the earlier of August 31, 2027 or the company’s 2027 annual stockholders’ meeting, subject to her continued service. No additional equity award will be made to her in connection with the 2026 annual meeting of stockholders, and no Rule 10b5-1 plan is reported.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 21,750 shares
Grant/Award
1 txn
Insider
WILSON KAREN J
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 21,750 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 21,750 contracts (Direct)
Footnotes (1)
- F1. The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders.
Key Figures
Stock options granted: 21,750 options
Exercise price: $2.70 per share
Underlying common shares: 21,750 shares
+3 more
6 metrics
Stock options granted
21,750 options
Annual non-employee director equity award to Karen J. Wilson on August 31, 2026
Exercise price
$2.70 per share
Exercise price for the 21,750 stock options granted on August 31, 2026
Underlying common shares
21,750 shares
Shares of Elicio Therapeutics common stock underlying the granted options
Expiration date
August 31, 2036
Expiration of the 21,750 stock options held by Karen J. Wilson
Vesting date trigger
Earlier of August 31, 2027 or 2027 annual meeting
Full vesting condition for the annual non-employee director option award
Shares following transaction
21,750 derivative securities
Total stock options held directly by Karen J. Wilson after the grant
Key Terms
Stock Option (Right to Buy), exercise price, annual non-employee director equity award, vest and become exercisable
4 terms
Stock Option (Right to Buy) financial
"security title is listed as Stock Option (Right to Buy) for the grant"
exercise price financial
"conversion or exercise price is shown as 2.7000 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
annual non-employee director equity award financial
"The stock option represents the annual non-employee director equity award"
vest and become exercisable financial
"shall vest and become exercisable in full on the earlier of"
FAQ
What insider transaction did ELTX disclose for director Karen J. Wilson?
Elicio Therapeutics disclosed that director Karen J. Wilson received a grant of 21,750 stock options on August 31, 2026 as her annual non-employee director equity award, covering an equivalent number of shares of common stock.
What is the exercise price of the stock options granted to the ELTX director?
The stock options granted to director Karen J. Wilson have an exercise price of $2.70 per share, allowing her to purchase Elicio Therapeutics common stock at that price once the options vest and become exercisable.
When do Karen J. Wilson’s ELTX stock options vest and become exercisable?
The options will vest and become exercisable in full on the earlier of August 31, 2027, the one-year anniversary of the grant, or the 2027 annual meeting of stockholders, provided she continues to provide services to the company through the vesting date.
What is the expiration date of the ELTX stock options granted to the director?
The stock options granted to director Karen J. Wilson will expire on August 31, 2036. After that date, any unexercised portion of the 21,750 options will no longer be exercisable for Elicio Therapeutics common stock.
Will Karen J. Wilson receive any additional ELTX equity award for the 2026 annual meeting?
No. The filing states that no additional equity award will be made to Karen J. Wilson in connection with Elicio Therapeutics’ 2026 annual meeting of stockholders beyond the 21,750 stock options granted on August 31, 2026.
Were Karen J. Wilson’s ELTX option grants made under a Rule 10b5-1 trading plan?
No. The Form 4 indicates that the Rule 10b5-1 checkbox is not checked, so the reported 21,750 stock option grant to director Karen J. Wilson was not reported as made under a Rule 10b5-1 trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
